MARKSANS vs RPGLIFE: Stock Comparison

Marksans Pharma Limited vs RPG Life Sciences Limited

Live data: 22 July 2026, 3:02 PM IST • Source: NSE and company filings

Marksans Pharma Limited is the larger company by market capitalisation. Marksans Pharma Limited shows a lower P/E, while RPG Life Sciences Limited shows a higher ROE, a higher dividend yield and faster revenue growth. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Side-by-side comparison of Marksans Pharma Limited and RPG Life Sciences Limited on live price, valuation, growth, profitability, leverage and quarterly shareholding. Highlighted values mark the more favourable of the two on that metric's usual reading; a single metric is never the full story.

On standard readings, MARKSANS is more favourable on 4 of 13 scored metrics and RPGLIFE on 9These counts are context-free and are not an overall rating.

Key Differences

Market Cap
MARKSANS is the larger company
₹10,928 Cr vs ₹4,948 Cr
P/E Ratio
MARKSANS has a lower P/E
28.31x vs 43.37x
P/B Ratio
MARKSANS has a lower P/B
3.91x vs 8.25x
EPS
RPGLIFE has higher earnings per share
₹69.65 vs ₹9.71
Dividend Yield
RPGLIFE has a higher dividend yield
0.75% vs 0.29%
Revenue Growth (TTM YoY)
RPGLIFE has faster revenue growth
23.6% vs 20.8%
EPS Growth (TTM YoY)
MARKSANS has faster EPS growth
63.5% vs -74.5%
Qtr Sales Growth
RPGLIFE has stronger quarterly sales growth
23.6% vs 20.8%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Profile

MetricMARKSANSRPGLIFE
SectorHealthcareHealthcare
IndustryPharmaceuticalsPharmaceuticals

Price

MetricMARKSANSRPGLIFE
Live Price₹240.85₹3,001
Day Change-7.47%0.1%
Volume37.94 L30,154
52-Week High₹281.6₹3,082
52-Week Low₹155₹1,733
Distance from 52W High-14.47%-2.63%

Valuation

MetricMARKSANSRPGLIFE
Market Cap₹10,928 Cr₹4,948 Cr
P/E Ratio28.31x43.37x
P/B Ratio3.91x8.25x
EPS₹9.71₹69.65
Book Value₹66.74₹366.04
Dividend Yield0.29%0.75%

Growth

MetricMARKSANSRPGLIFE
Revenue Growth (TTM YoY)20.8%23.6%
EPS Growth (TTM YoY)63.5%-74.5%
Qtr Sales Growth20.8%23.6%
Qtr Profit Growth63.6%33.7%

Profitability & Leverage

MetricMARKSANSRPGLIFE
ROE15.2%19.3%
ROCE18.8%25.7%
Net Margin14.16%29.25%
Operating Margin20.4%20.9%
Debt to Equity0.11x0.03x

Shareholding

As of Mar 2026 • change vs previous quarter
MetricMARKSANSRPGLIFE
Promoter Holding43.87%72.95%
FII Holding16.76% 8.64 pp0.87% 0.13 pp
DII Holding6.57% 0.66 pp7.45% 0.41 pp
Public Holding32.79% 9.3 pp18.73% 0.28 pp

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: Marksans Pharma Limited and RPG Life Sciences Limited.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.